Purpose in Action: Susan G. Komen's 2025 Impact Report on Progress and Urgent Needs in the Fight Against Breast Cancer
Susan G. Komen®, the world's leading breast cancer organization, today released its 2025 Annual Impact Report, highlighting a year of progress made possible by the dedication of its donors, volunteers and partners.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513335744/en/
Progress Highlights from Susan G. Komen's® 2025 Impact Report
Breast cancer is the second leading cause of cancer death among women in the U.S. and is the most common cancer among women worldwide. What's more, it's estimated that more than 168,000 people in the U.S. are living with metastatic breast cancer (MBC), also known as stage 4, the most advanced and incurable stage of breast cancer. This year alone, nearly 43,000 people in the U.S. are expected to die from breast cancer — with MBC responsible for most of these deaths.
Komen's impact report highlights the critical progress made in the fight against breast cancer made possible by the passionate dedication of its donors, volunteers and partners — and the hope for a brighter future driven by its nationwide community. Komen believes that to save lives, the community must focus on conquering aggressive and metastatic breast cancers and eliminating barriers to care to achieve health equity.
To achieve the organization's goals, to date, Komen has invested nearly $2.5 billion in advocacy, community programs, education and patient support services, ensuring people are educated about the complexities of risk, screening, diagnosis and treatment for breast cancer and have access to the care they need. Komen has also invested nearly $1.1 billion in research making it the largest nonprofit contributor to the cause, second only to the U.S. government. This investment has led to new ways to prevent, detect, diagnose and treat breast cancer.
'Susan G. Komen's impact is woven into nearly every major breakthrough and patient-centered policy in the history of breast cancer, but we could never have come this far without the support of our community,' said Paula Schneider, Komen president and CEO. 'Our donors, volunteers, partners and fundraisers are the heart of our history and frankly, our future. Many come to Komen because they've been personally touched by this disease — and, as a breast cancer survivor, myself included. There is power in pain and hope alike, and the progress we've made is a testament to those who've turned their experience and grief into action.'
Key Highlights from Komen's 2025 impact report include:
With proposed federal budget cuts for Fiscal Year 2026 threatening to erode decades of progress in the fight against breast cancer, continued funding especially for early detection programs, safety net care services and research has never been more critical. If these cuts proceed, Susan G. Komen will continue to stand as the leading breast cancer organization in the nation — but without sustained government support, lifesaving breakthroughs may be delayed, early detection efforts will be reduced, and patients will be left behind with poor outcomes to follow.
As Komen continues to lead the charge against breast cancer, the 2025 Impact Report serves as both a reflection of what's been achieved and a call to action for what still needs to be accomplished. Every advancement — whether in research, patient care, education or policy — is fueled by the commitment of those who stand with Komen.
'With continued support, we can build on these incredible milestones to ensure everyone affected by this disease has access to the high-quality care, resources and support they need to survive and thrive after breast cancer,' added Schneider. 'The fight is far from over — but together, we will finish it.'
Read the full report online.
About Susan G. Komen ®
Susan G. Komen ® is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy's life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow's cures. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social at www.komen.org/contact-us/follow-us/.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250513335744/en/
CONTACT: Media Contact:
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA TEXAS
INDUSTRY KEYWORD: PUBLIC POLICY PHARMACEUTICAL ONCOLOGY GENERAL HEALTH WOMEN PHILANTHROPY ADVOCACY GROUP OPINION PUBLIC POLICY/GOVERNMENT FUND RAISING FOUNDATION SCIENCE OTHER PHILANTHROPY OTHER SCIENCE CONSUMER RESEARCH HEALTH
SOURCE: Susan G. Komen
Copyright Business Wire 2025.
PUB: 05/13/2025 10:29 AM/DISC: 05/13/2025 10:28 AM
http://www.businesswire.com/news/home/20250513335744/en
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
BetterRX Named to Inc. 5000 Again; Continues to Set New Standard.
SALT LAKE CITY, August 20, 2025--(BUSINESS WIRE)--Earlier this month, BetterRX was named to the 2025 Inc. 5000 list of fastest growing companies in the U.S. for the second year in a row, moving from No. 3554 to 2437. Over the past three years BetterRX has achieved an impressive 174% revenue growth as they continue to displace outdated PBMs and become the hospice pharmacy provider of choice. Because traditional PBMs were not designed for hospice workflows, they often contribute to medication delays, nurse frustration, and inflated pharmacy costs. BetterRX was built to solve these exact problems, with faster fulfillment, technology that saves nurses time, and lower medication spend. "We've built a category-defining platform that's transforming how hospice care teams work," said Ben Clarke, who served as President and then CEO during the company's rise. "I'm incredibly proud of what we've accomplished and of the team driving it forward." Over 345,000 Patients Served. 6.4 Million Prescriptions Delivered. BetterRX has now helped more than 345,000 patients receive timely, reliable medications and has processed over 6.4 million e-prescriptions nationwide. Its platform has delivered results that have set a new standard for how hospice pharmacy should be done: Nurses save 5 to 6 hours each week, allowing more time with patients Net Promoter Score of 90+, among the highest in healthcare tech Net revenue retention of 114% over the past three years "Hospice providers across the country are walking away from outdated pharmacy benefit managers and choosing BetterRX — a faster, simpler, and fully transparent platform purpose-built for hospice care," said Clarke. Scaling the Mission with BVP Forge To support its next phase of growth, BetterRX recently secured a strategic investment from BVP Forge, the growth fund of Bessemer Venture Partners. As part of this new chapter, Tim Tannert, a healthcare executive who began his career as a pharmacist and previously served as CEO of SoftWriters, has been appointed CEO. "BetterRX is a category-defining platform with clear proof of its impact on patient care and nurse efficiency," said Tannert. "Now we're scaling it. The need for better hospice pharmacy isn't going away. We're here to make sure no nurse wastes another hour and no patient waits in pain. I couldn't be more proud to work with this team on the next chapter of growth and to help more patients and families get the care they deserve." After 13 years in executive leadership, Clarke made the personal decision to step away from day-to-day operations. He will continue to support BetterRX as a board member. BVP Forge will provide strategic support through its ForgeEdge program, helping BetterRX scale operations, expand pharmacy partnerships, and deliver on its mission across the country. About BetterRX BetterRX is redefining hospice pharmacy care. As the leading hospice pharmacy platform, BetterRX combines best-in-class technology, the most reliable pharmacy fulfillment, and exceptional 24/7 clinical and customer support, setting a new standard for speed, efficiency, and trust in end-of-life care. BetterRX helps providers reduce medication costs, save critical nurse time, and deliver faster, better care to patients and families, because when it comes to hospice, every moment matters. Hospices of every size, from local agencies to national leaders, are turning to BetterRX as the trusted partner to optimize care, control costs, and transform the hospice experience for those who need it most. Visit View source version on Contacts James JarmanVP of Marketingjjarman@ 385-252-9033 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Doppsee, Park Park Zoo's eastern black rhino, in critical condition
LANSING - Despite weeks of treatment and some improvement at times, Potter Park Zoo's eastern black rhino is in critical condition, zoo officials said. Doppsee, 18, experienced "a medical emergency" on July 28. Zoo staff determined that emergency to be an obstruction, the zoo said on July 31. In an Aug. 19 statement, zoo officials said Doppsee's condition had worsened. "As many of you know, the zoo's female eastern black rhino, Doppsee, has been undergoing treatment for several weeks by a team of veterinarians led by Dr. Ronan Eustace, our Director of Animal Health," officials wrote in a statement on Facebook. "Doppsee's condition has gone up and down throughout the treatment as she seems to respond positively to treatment and then regresses. Her condition is currently critical as we continue to do everything we can to help her recover. We thank you for keeping our entire team in your thoughts as they continue to work tirelessly to treat and monitor Doppsee." The zoo had announced the illness on July 29, one day after 'her behaviors indicated a very sudden decline in her health.' Veterinarian Ronan Eustace, the zoo's director of animal health, said staff noticed signs that were "acute in nature." Doppsee stopped eating and seemed to be uncomfortable and much quieter than usual, he said. There were signs of colic, he said. Doppsee came to the Lansing zoo in 2011, Her pairing with Phineus in 2017 produced a male calf born in December 2019. The calf was named Jaali. Black rhino births in captivity are relatively rare, and Jaali, the first black rhino calf ever born at Potter Park Zoo, captured the hearts of animal fans around the world. Jaali was moved to Living Desert Zoo and Gardens in California in 2021 and paired with a female rhino from a zoo in Ohio as part of the Species Survival Plan, said Amy Morris-Hall, executive director of the Potter Park Zoological Society. The eastern black rhino is critically endangered, with an estimated 5,000 living in the wild, Morris-Hall said. There are about 57 black rhinos living at zoos, she said. This article originally appeared on Lansing State Journal: Doppsee, Park Park Zoo's eastern black rhino, in critical condition Solve the daily Crossword
Yahoo
20 minutes ago
- Yahoo
The Chemo Mouthpiece® Medical Device Significantly Reduces Oral Pain and Opioid/Analgesic Use During Chemotherapy in Multi-Center Pivotal Clinical Trial
Peer-reviewed results published in Supportive Care in Cancer, the official journal of the Multinational Association of Supportive Care in Cancer (MASCC). WILMINGTON, Del., Aug. 20, 2025 /PRNewswire/ -- Chemomouthpiece, LLC, a privately held medical device company that develops and commercializes supportive cancer care products, today announced the peer-reviewed results from its pivotal, multi-center, randomized, controlled trial were published in Supportive Care in Cancer, the official journal of the Multinational Association of Supportive Care In Cancer (MASCC). The study, "Multi-institutional, randomized, controlled trial to assess the efficacy and tolerability of a reusable, self-contained cryotherapy delivery device", evaluated the Chemo Mouthpiece®, an FDA 510(k) cleared intraoral cryotherapy device, and demonstrated statistically significant reductions in patient-reported oral pain and opioid or analgesic use during chemotherapy treatment. Use of the Chemo Mouthpiece resulted in a 46% reduction in patient-reported oral pain symptoms compared to the control group. Additionally, there was a 68% reduction in opioid or analgesic use compared to the control group. The device showed efficacy across more than 30 chemotherapy regimens and 17 cancer types. The Chemo Mouthpiece was well-tolerated by patients, with no reported safety issues. Notably, 83% of patients indicated they would recommend the device for patients undergoing chemotherapy. A Practical Advancement in Oral Mucositis Management"Cryotherapy is a well-established strategy for mitigating oral mucositis, but its traditional delivery using ice chips presents practical challenges for patients and care teams," said Stephen Sonis, DMD, DMSc, Senior Lecturer in Oral Medicine at the Harvard School of Dental Medicine and a member of the senior faculty at the Dana-Farber Cancer Institute and Brigham and Women's Hospital. "The data from this trial indicate that cryotherapy delivered by the Chemo Mouthpiece provided patients with an effective and well-tolerated alternative to ice that could be used throughout their treatment period, both in the clinic and at home. Chemo Mouthpiece-delivered cryotherapy reduced patients' symptoms and need to rely on analgesics for pain management." Richard Zuniga, MD, Medical Chief of Research at New York Cancer and Blood Specialists and lead study investigator, said, "The data from this rigorous, multi-center trial clearly validate the Chemo Mouthpiece as a safe and effective tool for addressing oral mucositis-related pain and related opioid use. The scope of chemotherapy regimens and cancer types included in the study underscores the potential to benefit the diverse patient population impacted by oral mucositis. These findings represent a meaningful step forward in supportive oncology care." Innovation Driven by Personal Experience The Chemo Mouthpiece device was developed by company founder and CEO David Yoskowitz, a cancer survivor who experienced firsthand the debilitating effects of oral mucositis from chemotherapy and the lack of effective, tolerable options. At the time, his treatment options included ice chips to mitigate and minimize oral pain; however, they often caused nausea, were difficult to maintain in his mouth, and failed to effectively cool the entire oral cavity. These challenges led him to engineer a better solution. "This study is not just a scientific milestone, it's deeply personal," said Yoskowitz. "It's incredibly rewarding to see the clinical data confirm the device's impact on pain reduction and patient quality of life. Not only for me, but for our original goal, to help reduce the suffering associated with oral mucositis for every at-risk patient." About the TrialThe randomized trial enrolled 164 patients undergoing chemotherapy and assigned them in a 2:1 ratio to receive either the Chemo Mouthpiece plus best supportive care (arm A) or best supportive care alone (arm B) across 16 U.S. study sites. Inclusion criteria allowed broad tumor diagnoses and chemotherapy regimens. Patients used the device during infusion and for five days post-infusion across two treatment cycles. They completed daily questionnaires to assess oral pain and analgesic use. Device tolerability was also assessed via patient surveys. Unlike traditional oral cryotherapy approaches, which are generally recommended only for chemotherapy drugs with a short half-life during infusion, the trial included regimens with both short and long half-life agents. The portability, tolerability, and user-friendly design of the Chemo Mouthpiece made it practical for patients to continue use at home, when chemotherapy agents may still be circulating in the body. This extended use was associated with improved efficacy across a variety of chemotherapy regimens. The study was published in Supportive Care in Cancer, the official journal of MASCC: Zuniga, R., Dembla, V., Alam, N. et al. Multi-institutional, randomized, controlled trial to assess the efficacy and tolerability of a reusable, self-contained cryotherapy delivery device. Support Care Cancer 33, 732 (2025). About Oral MucositisOral mucositis is a painful and often debilitating side effect of chemotherapy, characterized by inflammation and ulceration of the mucous membranes in the mouth. It can interfere with a patient's ability to eat, drink, speak, and sleep and ultimately can reduce quality of life and delay treatment. Clinical impacts may include: Delays or dose reductions in cancer therapy Increased risk of infection due to open oral wounds Significant weight loss and nutritional challenges Greater dependence on opioids and analgesics Higher rates of ER visits and hospitalizations Increased financial and emotional burden for patients About the Chemo MouthpieceThe Chemo Mouthpiece is a self-contained cryotherapy device designed to cool the entire oral cavity during and after chemotherapy infusion. By inducing vasoconstriction in the oral cavity, the device reduces the local presence of chemotherapy drugs, helping to mitigate mucosal injury. Available by prescription only, the device is reusable, pre-filled, and designed for use in both the clinic and at home when chemotherapy may still be circulating, supporting utility across short‑ and long half‑life regimens. The FDA awarded the Chemo Mouthpiece Breakthrough Device Designation in December 2021 and the device was FDA 510(k) cleared in January 2024. INDICATION FOR USE: (Rx only) The Chemo Mouthpiece® is intended to be used to cool the oral mucosa to reduce the incidence and severity of chemotherapy induced oral mucositis in adult patients. See Important Safety Information at About Chemomouthpiece, LLCChemomouthpiece, LLC is a privately held medical device company headquartered in Wilmington, Delaware. Founded by a cancer survivor, the company's mission is to bring patient-driven innovation to the forefront of supportive oncology care. The Chemo Mouthpiece® is the company's flagship product, designed to help reduce the incidence and severity of oral mucositis, one of the most common and painful side effects of chemotherapy, impacting up to 80% of patients depending on cancer type. This release contains forward-looking statements regarding Chemomouthpiece, LLC, including its potential benefits and future development plans, which are subject to risks and uncertainties that may cause actual results to differ. The Company undertakes no obligation to update these statements except as required by law. For more information on Chemomouthpiece, LLC, please visit our website at or contact; Scott Narins, Director of Investor Relations snarins@ or Bonni Tattoli, VP, Commercial Operations at btattoli@ View original content to download multimedia: SOURCE Chemomouthpiece, LLC 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
